MVA mosaic vector vaccine regimens with gp140
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MVA mosaic vector vaccine regimens with gp140, covering 2020-11-04 to 2020-11-04. Get the full timeline:
Most recent: Clinical Trial Update: Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention [Phase 1, Phase 2]